S Korea’s IMM to buy Kolmar Holdings’ pharma contract manufacturing, drug biz for $413m

South Korea-based IMM Private Equity plans to acquire Kolmar Korea Holdings’ pharmaceutical contract manufacturing organisation and its drug development business for $413 million (KRW512.4 million), according to media reports.

Kolmar Korea said that its toothpaste business, which is part of its pharmaceutical business unit, will not be included in the sale, according to the company’s filing, AVCJ reported.